West Pharmaceutical Services Inc (WST)

被高估

HealthcareMedical Instruments & SuppliesUnited States

基本面

价格

$366.07

市值

$26.44B

Yahoo Finance TradingView 新闻官网

第一部分 · 这家公司值多少

概览

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

资产负债表与流动性

营收

$3.33B

最近12个月（截至2026/6/30）

净利润

$565M

最近12个月（截至2026/6/30）

自由现金流

$469M

股东权益合计

$3.18B

负债合计

$1.09B

流动比率

2.82

利息覆盖率

151.20

债务/EBITDA

0.42

每股收益

营收与净利润

自由现金流

收入构成

历史财务表

利润率变化

债务变化

债务负担有多重

增长一览表

增长 — 营业收入

公允价值估算

一般情形被高估

公允价值

$258.38

当前价格

$366.07

安全边际

-41.7%

公允价值区间

$167.95 - $348.82

所用估值方法之间的离散区间，并非经过统计校准的置信区间。

估算方法

分析师目标价:$407.56

现金流折现法（DCF）:$111.64

市盈率法（P/E）:$298.06

格雷厄姆成长公式:$171.74

盈利能力价值（EPV）:$69.50

合理市净率（P/B）:$93.50

股息折现模型（戈登模型）:$12.89

P/FFO（运营资金）:$151.21

周期中段收益:$125.31

市销率法（P/S）:$183.83

分析师共识:强力买入 (21B / 2H / 0S)

最近财报超预期:+12.77%

估值指标

市盈率（P/E）

47.47

ROE

15.5%

市净率（P/B）

8.73

P/FCF

59.72

毛利率

36.8%

ROIC

15.6%

盈利能力雷达图

价值创造（经济护城河）

ROIC

15.6%

WACC

10.7%

ROIC − WACC

+4.9 pp

ROIC 超过资本成本：公司正在为股东创造价值。

基本面分析标准

通过（21）

EPS shows upward trend
EPS CAGR 6.05%
Price CAGR 15.10%
ROIC 15.6%
Gross Margin 36.8%
Debt/Equity ratio
Operating Margin 20.5%
Positive Free Cash Flow
Current Ratio
Interest Coverage
Debt/EBITDA
Return on Tangible Assets
Low reliance on intangibles
ROE 18.5%
Revenue Growth 5Y 7.4%
Analyst Consensus 91% Buy
Earnings Surprise avg 16.0%
Earnings Quality (OCF/NI) 1.17
Share Dilution -1.3%
Net Margin Trend 17.0% vs 16.5%
Piotroski F-Score 7/9

未通过（6）

P/FCF 59.72
P/B Ratio 8.73
CapEx intensity
Price below Graham Number
DCF valuation (Overvalued)
PEG Ratio 5.59

不可用（1）

Dividend Payout NaN%

Piotroski F-评分

7/9

财务状况强健

score

criteria

盈利质量

1.17

高质量：盈利有现金流支撑

股权稀释

-1.3%

正在回购股份，对股东友好

机构持股

公司治理

管理团队

姓名	职位	年龄
Mr. Robert W. McMahon C.M.A.	Senior VP & CFO	56
Ms. Annette F. Favorite	Chief HR Officer & Senior VP	60
Mr. Shane A. Campbell	SVP & Chief Proprietary Segment Officer	45
Mr. Michel Lagarde	President, CEO & Director	50
Mr. Chad R. Winters	VP of Finance & Chief Accounting Officer	46
Dr. Devesh Mathur	Senior VP & CTO	-
Mr. John P. Sweeney C.F.A.	Vice President of Investor Relations	-
Mr. Norman D. Finch Jr.	Senior VP, General Counsel & Corporate Secretary	60
Ms. Michele Polinsky	Vice President of Global Communications	-
Mr. Rudy J. Poussot	Senior Vice President of Strategy & Corporate Development	55

审计风险

董事会风险

薪酬风险

股东权利风险

第二部分 · 价格与买入时机

这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。

文件

年度报告（10-K）
对公司业务、财务业绩和风险的年度概述。
提交日期：2026-02-17
查看文件
季度报告（10-Q）
最近三个月财务表现的最新情况。
提交日期：2026-07-23
查看文件
临时报告（8-K）
关于重大事件（如管理层变动或重要公告）的通知。
提交日期：2026-07-23
查看文件

via SEC EDGAR

损益历史

via SEC EDGAR

Latest News

Recent headlines for WST, sourced from Markets Gazette.

4/23/2026POSITIVE
West Pharmaceutical Lifts Annual Guidance After Strong GLP-1 Driven Growth In Q1
West Pharmaceutical Services Inc. reported Q1 results that surpassed analyst expectations, driven by robust demand for GLP-1 drug delivery components. The company has consequently raised its full-year 2026 financial guidance, signaling strong confidence in continued growth. Furthermore, West Pharmaceutical announced a new $1 billion share repurchase program, indicating a commitment to returning capital to shareholders. This combination of exceeding current performance, improving future outlook, and enhancing shareholder value makes the stock an attractive prospect for investors.

via Markets Gazette